Comparative Pharmacology
Head-to-head clinical analysis: ISOVUE 300 versus ISOVUE M 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOVUE 300 versus ISOVUE M 300.
ISOVUE-300 vs ISOVUE-M 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiocontrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and body cavities during imaging procedures.
Iopamidol is a nonionic, low-osmolality iodinated contrast agent that attenuates X-rays by increasing the density of tissues, thereby enhancing the visibility of vascular structures and organs during imaging procedures. It acts by absorbing X-rays due to the high atomic number of iodine.
Intravenous: 50-150 mL (up to 300 mg iodine/kg) as a bolus or infusion; intra-arterial: 5-40 mL depending on procedure; intrathecal: 8-15 mL. Maximum total iodine dose: 300 mg iodine/kg.
1.0-2.0 mL/kg intravenous bolus for CT imaging up to a total of 150 mL per procedure; intra-arterial dosing varies by procedure, typical adult dose 30-60 mL per injection.
None Documented
None Documented
Terminal elimination half-life in patients with normal renal function is approximately 2 hours. In patients with moderate to severe renal impairment (creatinine clearance <30 mL/min), the half-life can be prolonged up to 20–40 hours, requiring dose adjustment.
Terminal elimination half-life: approximately 2 hours (range 1.5–2.5 hours). Normal renal function; prolonged in renal impairment.
Primarily renal (glomerular filtration), with >95% of administered dose excreted unchanged in urine within 24 hours. Less than 1% is excreted via bile/fecal route.
Primarily renal excretion via glomerular filtration; unchanged drug: >95% excreted in urine within 24 hours. Biliary/fecal excretion: negligible (<1%).
Category C
Category C
Contrast Media
Contrast Media